Introduction {#s1}
============

Infectious diseases are caused by microorganisms (bacteria, viruses, fungi, parasites, etc.) releasing toxins or invading body tissues due to patients' poor constitution and insufficient resistance to pathogens ([@B21]). These diseases gravely threaten human health, and appropriate drug treatment represents an important management strategy ([@B48]). With increasing pressure of anti-infective drug selection, the spread of bacterial resistance and the slowdown of developing new drugs, many previously treatable infectious diseases have now become "incurable" ([@B23]). The problem of bacterial resistance is becoming a serious threat to global public health. An estimated 162,000 people die of multidrug-resistant infections in the United States each year ([@B10]). The diagnosis and treatment of infectious diseases are constantly facing new challenges. What are the current status and challenges in the prevention and treatment of common infectious heart diseases and surgical infections in cardiac disease field?

Cardiac-related infections include cardiac infectious diseases, cardiac device infections \[permanent pacemakers (PPMS) and implantable cardioverter defibrillators (ICD)\], and heart surgery-related infections ([@B19]). Many studies have shown microbial infections exhibit many pathogenic behaviors in cardiac-related infections, especially in bacterial and viral infections, which can directly lead to infective endocarditis (IE), myocarditis, pericarditis, cardiac device (permanent pacemakers, and implantable cardioverter defibrillators) implantation infections, and cardio-surgery infections ([@B20]; [@B7]; [@B29]; [@B27]; [@B31]; [@B24]). Many experts have devoted to developing relevant diagnosis and treatment principles and plans for antibiotic prevention ([@B44]). Guidelines released by the European Heart Association and the American Heart Association recommend patients with infective endocarditis on the left side of the heart to accept intravenous antibiotic therapy for 6 weeks ([@B5]; [@B22]). Intravenous therapy during long-term hospitalization may increase the risk of complications, while shorter hospitalization is associated with better outcomes ([@B8]). Besides, the incidence of right-side IE is increasing due to repaired congenital heart disease, the applying of injectable drugs, as well as the implantation of more cardiac devices including cardiac pacemakers, implantable cardioverters, and resynchronization devices ([@B13]). Therefore, given changes in pathogen spectrum and threats from antibiotic resistance, exploring better clinical diagnosis and treatment strategies remains necessary ([@B32]).

Clinical trials can provide valid evidence for the safety and efficacy of prevention, diagnosis, and treatment strategies ([@B12]). ClinicalTrials.gov is a clinical trial database jointly run by the National Library of Medicine (NLM) and the US Food and Drug Administration (FDA) under the National Institutes of Health (NIH). In European Union and the United States, registering all interventional clinical trials is mandatory ([@B47]). The International Committee of Medical Journal Editors (ICMJE) announced a policy in which the registration of clinical trials is stipulated to be a precondition for publication ([@B15]). ClinicalTrials.gov is the largest clinical trial registry, with high weekly growth rates for new entries, detailed information on past and present clinical trials, and high transparency and accessibility. Therefore, it could offer even more trials-obtained details than those reported in final peer-reviewed publications ([@B14]).

In recent years, with changes in pathogen spectrum and growing threats from antibiotic resistance, rational use of drugs faces challenges. Therefore, we limited our current analysis to clinical trials accessible at ClinicalTrials.gov to assess the characteristics of cardiac-related infection trials and the status of drug interventions.

Methods {#s2}
=======

Accessible records of all clinical trials registered at ClinicalTrials.gov were downloaded, using its advanced search function to search for the terms "cardiac disease, infection," "endocarditis," "pericarditis," "myocarditis," "coronary artery, infection," "aortitis," and "rheumatic heart disease" respectively for "condition or disease" on February 16, 2019. All types of studies were incorporated, including interventional (clinical trials), observational, and expanded studies. Trials of both open (not yet being recruited, recruited) and closed (enrolled through invitation; active, not recruited; suspended; terminated; completed; withdrawn; unknown status) statuses were considered for inclusion. No restrictions were imposed on study results or their enrolled patients' age. All diseases interested in study must be exactly caused by pathogenic microorganism. All included clinical trials must have definitive records on identified anti-infective drugs.

All the following information was extracted from each study: tracking information: actual start date of the study; descriptive information: study type, study phase, study design: interventional study (allocation, intervention model, masking, and primary purpose) and observational study (model, time perspective), number of arms, trial medications, study result, and online linked publications; recruitment information: recruitment status, actual enrollment, estimated completion date of the study, sex/gender, ages, and location; administrative information: National Clinical Trial (NCT) number, data on monitoring committee (DMC), primary study sponsor, collaborators, and funder type.

All trials were then further subdivided according to classification entry. Descriptive statistics were used to describe qualitative results. Percentage frequency distributions were adopted for categorical data.

Results {#s3}
=======

As of February 16, 2019, 297, 86, 21, 46, 42, 6, and 31 registered trials were identified on clinicaltrials.gov, using the terms "cardiac disease, infection," "endocarditis," "pericarditis," "myocarditis," "coronary artery, infection," "aortitis," and "rheumatic heart disease," respectively. We excluded duplicated studies and those using non-anti-infective drugs during initial review. In addition, we confirmed that each of the included studies focused diseases directly caused by the infection of pathogenic microorganisms during manual review process. After excluding 484 trials, 45 trials were eventually included (23 focusing on infective endocarditis, three on Chagas heart disease, two on coronary infection, one on parvovirus-mediated cardiomyopathy, one on tuberculous pericarditis, one on children with rheumatic heart disease, 1 on post-resuscitation infection after cardiac arrest and 13 on heart-related device/surgical infections, see [**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}).

General Characteristics of the Included Clinical Trials {#s4}
=======================================================

The enrolled trials were registered between 1999 and 2019, and most (86.7%) of them began between 2008 and 2019. Study duration was within 36 months in more than half of the trials (62.2%), between 36 and 72 months in 26.7% of the trials, and more than 72 months in 11.1% of the trials. Of the eligible trials, 41 (91.1%) were intervention trials and the other four (8.9%) were observational trials. Completed status was dominant in the included trials (*n* = 16, 35.6%), followed by recruiting status (*n* = 11, 24.5%). Seven trials (15.6%) were terminated (three lacking funds; two lacking statistical power; one due to business reasons; one due to expired commitment) and one was withdrawn (unable to recruit patients within specified time period. No patients had been enrolled in the study). Most trials actually enrolled a large number of participants; specifically, 62.2% recruited 100 or more participants, 20.0% more than 1,000 participants, and one even recruited 4,000 participants. The included trials were mainly focused on adult patients, that is, 39 (86.7%) only included adult patients, three included individuals less than or equal to 18 years old, and two included subjects younger than 18 years old ([**Table 1**](#T1){ref-type="table"}).

###### 

General characteristics of the included trials.

                             Number   Percent
  -------------------------- -------- ---------
  *Study start date*                  
   Prior to 2008             6        13.3
   2008--2010                11       24.5
   2011--2013                6        13.3
   2014--2016                10       22.2
   2017--2019                12       26.7
  *Length of study time*              
   0 \< L ≤ 36m\*            28       62.2
   36m \< L ≤ 72m            12       26.7
   L \> 72m                  5        11.1
  *Study type*                        
   Interventional            41       91.1
   Observational             4        8.9
  *Recruitment status*                
   Not yet recruiting        3        6.7
   Recruiting                11       24.5
   Enrolling by invitation   1        2.2
   Active, not recruiting    3        6.7
   Terminated                7        15.6
   Completed                 16       35.6
   Withdrawn                 1        2.2
   Unknown                   3        6.7
  *Actual enrollment*                 
   \<100                     17       37.8
   100--1,000                17       37.8
   1,000--2,000              7        15.6
   ≥2,000                    2        4.4
   NP                        2        4.4
  *Ages*                              
   \<18 years                2        4.4
   Up to 18 years            3        6.7
   18 years and older        39       86.7
   All                       1        2.2
  *Sex/gender*                        
   All                       45       100.0

\*m, month; NP, not provided.

Methodological Quality of the Included Clinical Trials {#s5}
======================================================

Information about clinical trial phase was available in 38 out of 41 interventional studies. Besides, 16 (39.0%) trials belonged to phase 3, 11 (26.8%) to phase 4, and 8 (19.5%) to phase 2. There were 32 (78.1%) trials contained two groups, while six (14.6%) only 1 group. Most trials (78.1%) were randomized. Most commonly adopted intervention model was parallel assignment (*n* = 32, 78.1%), followed by single group assignment (*n* = 5, 12.2%). Almost half of the trials (46.4%) were not masked, eight (19.5%) were single masked, and other eight (19.5%) were quadruple masked. Main objectives of the interventional trials lay in treating (61.0%) and preventing (34.2%). Of the four observational studies, two (50.0%) were cohort studies; meanwhile, three (75.0%) trials were prospective and one (25.0%) retrospective ([**Table 2**](#T2){ref-type="table"}).

###### 

Design data of the trials.

  Study type                                                Number   Percent
  --------------------------------- ----------------------- -------- ---------
  Interventional (clinical trial)   *Trial phase*                    
   Phase 1                          2                       4.9      
   Phase 1/phase 2                  1                       2.5      
   Phase 2                          8                       19.5     
   Phase 3                          16                      39.0     
   Phase 4                          11                      26.8     
   NP                               3                       7.3      
  *Number of arms*                                                   
   1                                6                       14.6     
   2                                32                      78.1     
   3                                1                       2.4      
   4                                2                       4.9      
  *Allocation*                                                       
   Non-randomized                   3                       7.3      
   Randomized                       32                      78.1     
   NP                               6                       14.6     
  *Intervention model*                                               
   Single group assignment          5                       12.2     
   Parallel assignment              32                      78.1     
   Factorial assignment             1                       2.4      
   Crossover assignment             3                       7.3      
  *Masking (blinding)*                                               
   Open label                       19                      46.4     
   Single                           8                       19.5     
   Double                           3                       7.3      
   Triple                           2                       4.9      
   Quadruple                        8                       19.5     
   NP (provided)                    1                       2.4      
  *Primary purpose*                                                  
   Treatment                        25                      61.0     
   Prevention                       14                      34.2     
   Health services research         1                       2.4      
   NP                               1                       2.4      
  Observational                     *Observational model*            
   Cohort                           2                       50.0     
   Other                            1                       25.0     
   NP                               1                       25.0     
  *Time perspective*                                                 
   Prospective                      3                       75.0     
   Retrospective                    1                       25.0     

NP, not provided.

Detailed Characteristics of the Included Clinical Trials {#s6}
========================================================

Among the 45 trials, 41 (91.1%) were conducted only on one continent, of which 17 (41.5%) were in North America, 12 (29.3%) in Europe, and six (14.6%) in Asia. Four trials (8.9%) were conducted on two or more continents, and one of them even involved individuals from four continents. Companies were listed as primary sponsors in 18 (40.0%) trials, universities in 11 (24.5%), and hospitals in six (13.3%). A small number of trials (28.9%) had collaborations, and one of them had nine collaborations. Most of the trials (64.5%) were supported by other-type funds, followed by industrial funds (24.4%). Less than half of the trials (48.9%) provided DMCs. Only six (13.3%) trials listed results at ClinicalTrials.gov. While 11 (24.4%) trials offered links to webpage publications displaying relevant results, and 10 (22.2%) were linked to PubMed citation through indexed NCT number of the studies. Most of the trials attached publications (72.7%) possessed more than two publications. Among the published trials, eight (72.7%) enjoyed an impact factor (IF) value no less than 5, and 27.3% no less than 40. ([**Table 3**](#T3){ref-type="table"}).

###### 

Detailed characteristics of the included trials.

                                        Number   Percent
  ------------------------------------- -------- ---------
  *Locations*                                    
   Single continent                     41       91.1
   Asia                                 6        14.6
   Europe                               12       29.3
   North America                        17       41.5
   South America                        2        4.9
   Africa                               3        7.3
   Oceania                              1        2.4
   Multiple continents                  4        8.9
   2 continents                         3        75.0
   \>2 continents                       1        25.0
  *Study sponsor*                                
   University                           11       24.5
   Hospital                             6        13.3
   Industry                             18       40.0
   Other                                10       22.2
  *Collaborators*                                
   NP                                   32       71.1
   Has collaborators                    13       28.9
  *Funder type*                                  
   Other                                29       64.5
   Other/industry                       4        8.9
   Industry                             11       24.4
   Industry/U.S. Fed                    1        2.2
  *Data monitoring committee*                    
   Has data monitoring committee        22       48.9
   Not have data monitoring committee   15       33.3
   NP                                   8        17.8
  *Study results*                                
   Has results                          6        13.3
   No results                           39       86.7
  *Publications of the study*                    
   No publications                      34       75.6
   Has publications                     11       24.4
   \<2 publications                     3        27.3
   ≥2 publications                      8        72.7
   IF of publications                            
   0 \< IF \< 5                         3        27.3
   5 ≤ IF \< 10                         2        18.2
   10 ≤ IF \< 40                        0        0.0
   IF ≥ 40                              6        54.5

NP, not provided.

Description of Drugs in the Included Clinical Trials {#s7}
====================================================

Experimental groups in all included trails involved 11 categories and 27 kinds of antibiotics. Of the 41 intervention trials, 37 compared for efficacy across different drugs, and four for different uses of same drugs (oral/intravenous antibiotics). Of the interventional trials, 25 investigated drugs for treatment, 15 for prevention, while one did not provide intervention targets. Among the trials on treatment, experimental group were mostly used to concentrate on antibiotics, three on anti-inflammatory drugs and one on vitamin supplement. Highly interested antibiotics in the trails were glycopeptides (*n* = 5), β-lactams (*n* = 5), and lipopeptides (*n* = 5). Daptomycin and vancomycin were most frequently discussed in experimental group. In control group, antibiotics appeared in all trials except in placebo/conventional treatment. β-Lactam antibiotics appeared most frequently, which included nine kinds of drugs. Vancomycin, gentamycin, and daptomycin were the most common single-drugs in control group. Among the trials on prevention, most experimental groups adopted antibiotics, two surgical area disinfectants and one probiotic. Most frequently applied antibiotics was glycopeptides (*n* = 4), and vancomycin represented the most commonly employed single-antibiotic. In control group, antibiotics and surgical area disinfectant were both focused on. Most frequently accepted antibiotics was β-lactams (*n* = 4), with cefazolin topping the list. In four observational studies, selected drugs mainly were antibiotics and hormones, and most popular antibiotics were quinolones. In addition, most trials (*n* = 31, 83.8%) evaluated old antibiotics, and six trials (16.2%) assessed new antimicrobials approved by the FDA in recent years ([**Table 4**](#T4){ref-type="table"}).

###### 

Descriptions of drugs in trials.

  Study type                        Primary purpose     Experimental group         Comparison group                                                       
  --------------------------------- ------------------- -------------------------- ------------------ ------------------- --------------------------- --- --
  Interventional (clinical trial)   Treatment           *Antibiotic drugs*                                                *Antibiotic drugs*              
                                    Glycopeptides       Vancomycin                 2                  β-Lactams           Ceftriaxone                 2   
                                                        Dalbavancin\*              1                                      Amoxicillin                 1   
                                                        Oritavancin\*              1                                      Amicillin                   1   
                                                        Telavancin                 1                                      Penicillin G                1   
                                    β-Lactams           Ceftriaxone                1                                      Cloxacillin                 1   
                                                        Benzathine penicillin G    1                                      Oxacillin                   1   
                                                        Imipenem                   1                                      Semi-synthetic penicillin   1   
                                                        Amoxicillin                1                                      Synthetic penicillin        1   
                                                        Ceftobiprole medocaril\*   1                                      Cefazolin                   1   
                                    Tetracycline        Doxycycline                1                  Aminoglycosides     Gentamycin                  4   
                                    Macrolides          Azithromycin               1                                      Netilmicin                  1   
                                    Antifungals         Fluconazole                1                  Glycopeptides       Vancomycin                  7   
                                    Quinolones          Levofloxacin               1                  Lipopeptides        Daptomycin                  3   
                                    Lipopeptides        Daptomycin                 5                  Other antibiotics   Rifampicin                  1   
                                    Aminoglycosides     Gentamicin                 1                                                                      
                                    Other antibiotics   Fosfomycin                 1                                                                      
                                                        CF-301\*                   1                                                                      
                                                        Benznidazole               1                                                                      
                                                        Rifabutin                  1                                                                      
                                                        Rifampicin                 1                                                                      
                                    *Others*            Selenium                   1                                                                      
                                                        Immunoglobulins            1                                                                      
                                                        Colchicine                 1                                                                      
                                                        Prednisolone               1                                                                      
  Prevention                        Antibiotic drugs                                                  Antibiotic drugs                                    
                                    Glycopeptides       Vancomycin                 4                  β-Lactams           Cefazolin                   2   
                                    β-Lactams           Cefazolin                  2                                      Cephalexin                  1   
                                    Tetracycline        D-PLEX^\*^                 2                                      Ceftaroline                 1   
                                    Antivirals          Valganciclovir             2                  Antivirals          Mycophenolate               1   
                                                        Mycophenolate              1                  Quinolones          Levofloxacin                1   
                                    Peptides            Polymyxin-B                1                  Lincomycin          Clindamycin                 1   
                                                        Bacitracin                 1                  Lipopeptides        Daptomycin                  1   
                                    Aminoglycosides     Gentamicin                 1                  Other antibiotics   Linezolid                   1   
                                    Other antibiotics   Mupirocin                  1                  *Others*            Chlorhexidine               1   
                                    *Others*            Povidone iodine            1                                                                      
                                                        Hydrogen peroxide          1                                                                      
                                                        Synbiotic 2000             1                                                                      
  NP                                Lipopeptides        Daptomycin                 1                                                                      
  Observational                     Treatment           Antibiotic drugs                                                                                  
                                                        Quinolones                 Trovafloxacin      1                                                   
                                                                                   Levofloxacin       1                                                   
                                                        Lipopeptides               CUBICIN            1                                                   
                                                        Other antibiotics          Fosfomycin         1                                                   
                                                        Others                     Hydrocortisone     1                                                   

\*U.S. FDA-regulated Drug Product; NP, not provided.

Description of Drugs in Varied Types of Cardiac-Related Infections {#s8}
==================================================================

Drugs adopted for the prevention and treatment of cardiac-related infections were mainly concentrated on antibiotics, antivirals, and glucocorticoids. Antivirals were often employed in treating coronary infections, especially valganciclovir. Glycopeptides, β-lactams, and tetracycline antibiotics were often applied to prevent or treat infections related to open heart surgery; peptide antibiotics were for infections associated with implantations surgery. Lipopeptides were most commonly studied, followed by β-lactams and glycopeptides among the IE caused by *Staphylococci*. Glycopeptides, especially vancomycin, most commonly appeared in methicillin-resistant *Staphylococcus aureus* (MRSA)-induced IE studies, while β-lactams in those on IE caused by *Enterococcus faecalis*. Glucocorticoids were most adopted in heart diseases that cause systemic infections. In addition, there were also other non-antibiotics involved. In these studies, especially those related to IE, three drugs were adopted to explore effects of different modes of administration (oral *vs* intravenous treatment), and one drug for pharmacokinetic characteristics of different doses and frequency ([**Table 5**](#T5){ref-type="table"}).

###### 

Description of drugs in varied types of cardiac-related infections.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Conditions/diseases                                             Experimental group                                           Comparison group                                                                                                         
  --------------------------------------------------------------- ------------------------------------------------------------ ----------------------------- ------------------------- ------------------------ --------------------------- ----------- ---
  Coronary infection                                              Coronary heart disease/Chlamydophila pneumoniae infections   Tetracycline                  Doxycycline               1                                                                

  Macrolides                                                      Azithromycin                                                 1                                                                                                                        

  Others                                                          Rifabutin                                                    1                                                                                                                        

  Cardiac allograft vasculopathy/Cytomegalovirus infection        Antivirals                                                   Valganciclovir                3                         Antivirals               Pre-emptive mycophenolate   1           

  Mycophenolate                                                   1                                                                                                                                                                                     

  Cardiac surgery infection                                       Cardiac surgery/SSIs                                         Glycopeptides                 Vancomycin                3                        β-Lactams                   Cefazolin   2

  β-Lactams                                                       Cefazolin                                                    2                                                                                                                        

  Tetracycline                                                    D-PLEX\*                                                     2                                                                                                                        

  Aminoglycosides                                                 Gentamicin                                                   1                                                                                                                        

  Antivirals                                                      Valganciclovir                                               1                                                                                                                        

  Others                                                          Mupirocin                                                    1                                                                                                                        

  Non-antibiotic                                                  Synbiotic 2000                                               1                                                                                                                        

  Implantations surgery/infections                                Non-antibiotic                                               Povidone iodine               1                         Non-antibiotic           Chlorhexidine               1           

  Hydrogen peroxide                                               1                                                            β-Lactams                     Cephalexin                1                                                                

  Others                                                          Fluconazole                                                  1                             Linkes                    Clindamycin              1                                       

  Peptide antibiotics                                             Polymyxin B/bacitracin                                       1                             Peptide antibiotics       Polymyxin B/bacitracin   1                                       

  Quinolones                                                      Levofloxacin                                                 1                                                                                                                        

  Infective endocarditis\                                         IE/bacterial                                                 Others                        Fosfomycin                1                                                                
  (IE)                                                                                                                                                                                                                                                  

  IE/microbial infection                                          Glycopeptides                                                Vancomycin                    1                         Aminoglycosides          Gentamycin                  1           

  IE/*Streptococci*, *Staphylococci* or *Enterococci* infecting                                                                Antibiotic therapy^\#^                                                                                                   

  IE/*Streptococcus-Enterococcus*                                 β-Lactams                                                    Amoxicillin^\#^               1                         β-Lactams                Amoxicillin                 1           

  Ampicillin                                                      1                                                                                                                                                                                     

  Penicillin G                                                    1                                                                                                                                                                                     

  Ceftriaxone                                                     1                                                                                                                                                                                     

  Aminoglycosides                                                 Vancomycin                                                   1                                                                                                                        

  Gentamicin                                                      1                                                                                                                                                                                     

  Netilmicin                                                      1                                                                                                                                                                                     

  IE/MRSA, *Streptococci*                                         Glycopeptides                                                Dalbavancin\*                 1                                                                                          

  IE/MRSA                                                         Glycopeptides                                                Vancomycin                    1                         Glycopeptides            Vancomycin                  2           

  Others                                                          Fosfomycin                                                   1                                                                                                                        

  β-Lactams                                                       Imipenem                                                     1                                                                                                                        

  Lipopeptides                                                    Daptomycin                                                   1                                                                                                                        

  IE/SA                                                           Lipopeptides                                                 CUBICIN                       1                         Lipopeptides             Daptomycin                  4           

  Daptomycin                                                      4                                                                                                                                                                                     

  Quinolones                                                      Levofloxacin^\#^                                             2                             Glycopeptides             Vancomycin               4                                       

  Trovafloxacin                                                   1                                                            β-Lactams                     Cloxacillin,              1                                                                

  Glycopeptides                                                   Telavancin                                                   1                             Oxacillin,                1                                                                

  Vancomycin                                                      1                                                            Semi-synthetic Penicillin     1                                                                                          

  Synthetic penicillin                                            1                                                                                                                                                                                     

  β-Lactams                                                       Ceftobiprole medocaril\*                                     1                             Cefazolin                 1                                                                

  Aminoglycosides                                                 Gentamici                                                    1                             Ceftaroline               1                                                                

  Others                                                          CF-301\*                                                     1                             Aminoglycosides           Gentamicine              2                                       

  Rifampicin,1^\#^                                                1                                                            Others                        Rifampicin                1                                                                

  Linezolid                                                       1                                                                                                                                                                                     

  IE/*Enterococcus faecalis*                                      β-Lactams                                                    Ceftriaxone^@^                1                         β-Lactams                Ceftriaxone                 1           

  Lipopeptides                                                    Daptomycin                                                   1                                                                                                                        

  IE/OUD                                                          Glycopeptides                                                Oritavancin injection\*       1                                                                                          

                                                                  OPAT^\#^                                                     1                                                                                                                        

  Infectious myocarditis                                          Chagasic myocardiopathy/*Trypanosoma cruzi*                  Others                        Benznidazole              1                                                                

  Non-antibiotic                                                  Selenium                                                     1                                                                                                                        

  Colchicine                                                      1                                                                                                                                                                                     

  Myocardial diseases/\                                           Non-antibiotic                                               Intravenous Immunoglobulins   1                                                                                          
  Parvovirus B19                                                                                                                                                                                                                                        

  Infectious valvulitis                                           RHD/group A *Streptococcus*                                  β-Lactams                     Benzathine penicillin G   1                                                                

  Infectious pericarditis                                         Tuberculous pericarditis/HIV                                 Non-antibiotic                Prednisolone              1                                                                

  CA/infection                                                    Post-resuscitation infection/infections                      Non-antibiotic                Hydrocortisone            1                                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*U.S. FDA-regulated Drug Product; ^\#^the oral treatment vs IV treatment; ^@^Different doses of the same drug; F, frequency; SSIs, surgical site infections; MRSA, methicillin-resistant Staphylococcus aureus; SA, Staphylococcus aureus bacteria; OPAT, outpatient parenteral antibiotic therapy; OUD, opioid use disorder; RHD, rheumatic heart disease; HIV, human immunodeficiency virus; CA, cardiac arrest.

Discussion {#s9}
==========

This study comprehensively analyzed drug trials registered on ClinicalTrials.gov, all of which explored the intervention of infectious heart diseases or cardiac-related surgery infections. Through the analysis, we found that the number of registered cardiac-related infectious diseases was less than that of infectious diseases related to other organs. In these trials, most took interventional design. One-third of the trials were completed and 15.6% terminated. Most intervention trials were in phase 3 or 4, randomized, parallel assignment, masking, and sufficient, and possessed large sample size. Meanwhile, 24.4% of the trials offered publication links accessing to study results, 13.3% uploaded their results, and less than half provided DMCs. Drugs for treatment were mainly antibiotics, with glycopeptides, β-lactams, and lipopeptides topping the list in experimental group, while glycopeptides dominated in experimental group among trails on prevention.

From the perspective of study design, the vast majority of the trials (78.1%) were randomized and parallel assignment with two arms. Randomization, an exceptionally powerful tool, largely prevents confusion and mitigates selection bias in treatment comparisons ([@B41]). Besides, 51.2% of the trials were blinded. Well-implemented masking simultaneously prevents measurement bias and placebo effects through balancing treatment effects ([@B17]). Meanwhile, 62.2% of the trials contained more than 100 participants, and 20.0% more than 1,000. Sample size affects many factors, like statistical power, effect size, population mean, and variance ([@B1]). Due to the lack of information on the ClinicalTrials.gov Registry, we failed to make accurate judgments. However, larger sample size can increase the accuracy of estimated treatment outcome in trail and results' credibility ([@B38]). The standardization of clinical study design is important in successfully implementing clinical research. Appropriate randomization method, adequate masking, and treatment assignment, selecting active comparator and reasonable target sample size are essential in realizing reliable (unbiased) treatment comparison ([@B36]). But many trials did not mention specific procedures for randomization, allocation concealment, or the phase of open label. Therefore, we could not determine whether they possessed high quality. Additionally, 37.8% of the trials spanned more than 36 months, and 11.1% even lasted beyond 72 months. As for study time prolonging, time-dependent bacterial resistance rate would become a significant confounding factor ([@B46]). Because of varied study duration periods, bacterial resistance rates were different. When comparing drug efficacy, this aspect would possibly bias research conclusion ([@B45]). However, most trials chose random enrollment to alleviate the impact of this aspect. Of the trials, 17.8% were terminated or withdrawn, mainly due to inadequate enrollment, followed by lacking statistical power and business reasons. In addition, only 13.3% of the trials included children. The shortage of funds for children's medication and insufficient drug development still represent major challenges facing clinical studies on children's medications ([@B2]). We hope that the government can introduce relevant policies to encourage more research institutions to conduct drug trials on children to establish optimal clinical treatment strategies.

The selected trails were implemented in six continents, and 8.9% of them were conducted in two or more continents. As shown on the official website, ClinicalTrials.gov is a database of global clinical studies receiving both private and public funds. It covers a wide geographical range, making us accessible to more comprehensive information on diseases and more reliable results. Of the eligible trails, 28.9% had collaborators. Large-scale multicenter trials, exceeding single-center ones, would facilitate the recruitment of enough patients, speed trials' progress ([@B9]), and improve research's external validity ([@B1]). However, to reduce the bias in study implementation, it is necessary for researchers in different institutions to accept uniform standards and to reach consistent understanding ([@B3]). Besides, 48.9% of the trials offered DMCs; while DMC is vital in maintaining scientific integrity in trials, the authenticity and accuracy of trial data, and the safety of studied participants ([@B18]). Only 13.3% of the trials showed results on ClinicalTrials.gov, partly due to the presence of various extensions and exemptions. The Food and Drug Administration Amendments Act of 2007 (FDAAA) demands to submit "basic results" for certain types of clinical trials within 1 year after experiment completion ([@B35]). Reporting study results is critical in advancing study progression and ensuring the safety of participants in clinical trials. Therefore, it is necessary to strengthen the supervision of online result publication ([@B25]). Among our selected trails, 24.4% offered web links to their publications with relevant results on ClinicalTrials.gov., of which 27.3% were published on top journals (IF ≥ 40). Good research design plays a crucial role in result publication ([@B16]). At the same time, we found that most of the trials (66.7%) on top journals were funded by universities, hospitals, and research institutions, and industry-funded ones accounted for only one-third. Recent evidence indicates that trials funded by industry sources are likely to be biased in favor of sponsors' products, thus causing obvious publication bias ([@B26]).

In general, the vast majority of the trials focused on treating or preventing the occurrence of infection adopting antibiotics. Six trials (16.2%) evaluated new antimicrobials approved by the FDA in recent years. Since many pathogens are more resistant to existing antibiotics, it has become particularly important to develop new antibiotics to improve time-related bacterial resistance rates ([@B34]). Two trials evaluated the efficacy and safety of different methods of using the same antibiotic. Given the global crisis of antimicrobial resistance, it is important to determine the optimal duration of applying intravenous and oral antibiotics and to form evidence-based recommendations about when to switch from intravenous to oral routes ([@B28]).

Diseases in the selected trials involved infective endocarditis (IE), Chagas heart disease, coronary infection, parvovirus-mediated cardiomyopathy, tuberculous pericarditis, childhood rheumatic heart disease (RHD), and heart-related device/surgery infections. Options are limited for treating endocarditis caused by MRSA. Vancomycin is the standard treatment for blood infections caused by MRSA, but its effect is limited in treating endocarditis caused by MRSA. Its bactericidal activity is weaker than that of β-lactams, showing low permeability in the valves, while debates still exist on its applicability ([@B16]). Many clinical trials have evaluated the efficiency of different types or doses of antibiotic treatments, such as daptomycin, CF-301, β-lactams, fosfomycin, dalbavancin, levofloxacin, and new glycopeptides (dalbavancin or oritavancin). Earlier researches also involved optimized antibiotics treatment options for IE patients with opioid use disorder (OUD), an infection that has recently doubled hospitalization rates. In addition, the effectiveness and safety of conversion from intravenous antibiotics to oral ones have also been well evaluated. The effect of Trypanosoma treatment on Chagas myocardiopathy caused by *T. cruzi* infection is still unclear. Benznidazole, colchicine, and selenium supplementation were included in the study to explore their clinical efficacy. Besides, two of our enrolled trials examined the effects of combined antibiotics or antiviral drugs on preventing changes in coronary vascular infections. In addition, an included trial investigated the effect of high-dose intravenous immunoglobulin on virus presence in patients with high load of parvovirus B19 in the heart. Tuberculous pericarditis is often accompanied by human immunodeficiency virus (HIV) infection, seeing poor prognosis, and a collected trial evaluated the efficacy and safety of adjunctive prednisolone therapy. Appropriate management for latent RHD has not been developed and no formal recommendations have been established. Some trials explored the prophylaxis and prognosis of intramuscular benzathine penicillin G (BPG). Despite the use of prophylactic systemic antibiotics, postoperative wound infections and infections associated with cardiac implantable electronic devices still represent serious threats after heart-related surgery ([@B30]; [@B4]), though many types of antibiotic treatment regimens have been compared and comprehensively analyzed. For example, when it comes to D-PLEX, vancomycin, mupirocin, etc., whether their applications should be directly intravenous, oral, topical, or through dressing during surgery has been constantly discussed.

According to published articles, patients with IE who received daptomycin treatment could reach similar outcomes to those treated with vancomycin, and such treatment could be used as a reasonable alternative ([@B20]). The combination of fosfomycin with imipenem prevents drug resistance caused by single drug, and small doses can achieve ideal efficacy with reduced side effects among IE patients ([@B16]). Fluoroquinolone combined with standard treatment does not improve treatment outcomes of *S. aureus bacteremia*, nor does it reduce mortality or the incidence of deep infection ([@B39]). In patients with stable clinical conditions and sufficient response to initial treatment, transformation from intravenous administration to oral antibiotic treatment is not inferior to continued intravenous antibiotic treatment. Oral antibiotic may also minimize problems associated with outpatient parenteral treatment, logistics, and monitoring, and the risks of complications associated with intravenous catheters (e.g., local and systemic infections, and venous thrombosis) ([@B24]). In a large randomized controlled trial, benznidazole significantly reduced the detection rate of parasitic infections in Chagas heart disease patients but did not significantly reduce the incidence of major clinical outcomes ([@B31]). Adjunctive prednisolone had no significant effect on major clinical outcomes ([@B27]). Gentamicin-impregnated dressing had no significant effect on the rate of wound infection in patients undergoing open cardiac surgery ([@B7]). Consequently, specific improvements in antibiotics, including the use of narrow-spectrum therapy, shortening treatment times, early transition from IV to oral therapy ([@B6]), and the development of new drugs to prevent and treat infections, are key strategies in combating antimicrobial resistance.

The process of preventing and treating infectious diseases is complicated. Choosing right medication regimen, especially antibiotic regimen, requires a combination of the characteristics of pathogenic microorganism, the duration of medication application, adverse events caused by medication, and other outcomes ([@B11]). For example, IE, one of the most common diseases associated with heart-related infectious diseases, is hard to be cured due to the characteristics of the infection itself, the bacterial species, and frequent comorbidities of the patients ([@B16]; [@B40]). A long treatment cycle (4--6 weeks of intravenously administered antibiotic agents) used to be required, and aminoglycoside often brings about side effect of nephrotoxicity ([@B5]). In addition, the rate of antibiotic-resistant strains is increasing, which makes the establishment of effective antibiotic regimes more complicated. For this reason, some alternatives have been explored: Native valve endocarditis (NVE) was often treated with penicillin G and gentamicin for synergistic coverage of *Streptococci*. Patients with a history of intravenous drug use were treated with nafcillin and gentamicin to cover for methicillin-sensitive *Staphylococci*. The emergence of MRSA and penicillin-resistant *Streptococci* led to changes in empiric treatment, with liberal substitution of vancomycin in lieu of a penicillin antibiotic ([@B37]). Treatment options range from in-hospital intravenous antibiotic therapy to partial oral therapy, replacement has minimized challenges associated with outpatient parental treatment ([@B8]). Treatment offers the possibility of benefiting more patients, with multidisciplinary collaborative approach for the management of IE ([@B42]).

A recent review published in *Nature Reviews Immunology* ([@B33]) presented a unique perspective on new drugs for the intervention of infectious diseases. As a host-directed treatment, statins wield powerful effects against infectious diseases caused by viruses, parasites, fungi, and bacteria. In particular, statin-mediated destructive effects, in combination with standard therapies, could interfere with microdomain lipids of MRSA, thus providing a novel anti-multidrug resistance infection strategy ([@B43]). However, we still need proof-of-concept clinical studies and large randomized controlled trials to verify the feasibility of statins acting as potential replacement therapy in infectious diseases.

Our research still had some limitations: 1) Clinical trials were obtained only from ClinicalTrials.gov, though this source contains most of global trials; and we might miss some trials registered in other 11 registries ([@B47]) that were not fully evaluated. 2) Regarding to trial search and data extraction performed in this study, although all words supporting extensive research were used to maximize the number of included trials, some studies related to cardiac infection may not be found. 3) Since all information was obtained from ClinicalTrials.gov, intelligence not in this source was not further evaluated. At the same time, we only interpreted results acquired through ClinicalTrials.gov online links, and no more relevant publications were manually retrieved in the National Center for Biotechnology Information (NCBI) database using registration numbers. 4) Although final conclusions were relatively reliable based on publications with online links, considering that most of them were published in high-scoring journals, final establishment of clinical treatment methods need to take clinical therapies into account, after referring to more high-quality articles.

Conclusions {#s10}
===========

Our study comprehensively analyzes the characteristics of trials registered at ClinicalTrials.gov for drug prevention or treatment of cardiac-related infections. Most clinical trials were interventional RCTs for treatment. While the majority of interested drugs were old antibiotics, and few trials reported valid study results. It is necessary to strengthen supervision over the improvement of trial results, and to implement explorations combining antibacterial activity with drug delivery regimens to achieve optimal clinical outcomes.
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